GURUFOCUS.COM » STOCK LIST » USA » NAS » Moderna Inc (NAS:MRNA) » Definitions » ROE %
Switch to:

Moderna ROE %

: 50.13% (As of Jun. 2022)
View and export this data going back to 2018. Start your Free Trial

ROE % is calculated as Net Income attributable to Common Stockholders (Net Income minus dividends to participating security holders) divided by its average Total Stockholders Equity over a certain period of time. Moderna's annualized net income attributable to common stockholders for the quarter that ended in Jun. 2022 was $8,788 Mil. Moderna's average Total Stockholders Equity over the quarter that ended in Jun. 2022 was $17,530 Mil. Therefore, Moderna's annualized ROE % for the quarter that ended in Jun. 2022 was 50.13%.

The historical rank and industry rank for Moderna's ROE % or its related term are showing as below:

MRNA' s ROE % Range Over the Past 10 Years
Min: -39.99   Med: -37.04   Max: 146.08
Current: 106.42

During the past 6 years, Moderna's highest ROE % was 146.08%. The lowest was -39.99%. And the median was -37.04%.

MRNA's ROE % is ranked better than
98.96% of 1439 companies
in the Biotechnology industry
Industry Median: -38.43 vs MRNA: 106.42

Moderna ROE % Historical Data

The historical data trend for Moderna's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROE %
Premium Member Only -36.78 -37.29 -38.00 -39.99 146.08

Moderna Quarterly Data
Dec16 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 210.97 158.45 160.47 93.71 50.13

Competitive Comparison

For the Biotechnology subindustry, Moderna's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Moderna ROE % Distribution

For the Biotechnology industry and Healthcare sector, Moderna's ROE % distribution charts can be found below:

* The bar in red indicates where Moderna's ROE % falls into.



Moderna ROE % Calculation

Moderna's annualized ROE % for the fiscal year that ended in Dec. 2021 is calculated as

ROE %=Net Income attributable to Common Stockholders (A: Dec. 2021 )/( (Total Stockholders Equity (A: Dec. 2020 )+Total Stockholders Equity (A: Dec. 2021 ))/ count )
=12202/( (2561+14145)/ 2 )
=12202/8353
=146.08 %

Moderna's annualized ROE % for the quarter that ended in Jun. 2022 is calculated as

ROE %=Net Income attributable to Common Stockholders (Q: Jun. 2022 )/( (Total Stockholders Equity (Q: Mar. 2022 )+Total Stockholders Equity (Q: Jun. 2022 ))/ count )
=8788/( (17075+17985)/ 2 )
=8788/17530
=50.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income attributable to common stockholders of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income attributable to common stockholders data used here is four times the quarterly (Jun. 2022) net income attributable to common stockholders data. ROE % is displayed in the 30-year financial page.


Moderna  (NAS:MRNA) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %**(Q: Jun. 2022 )
=Net Income/Total Stockholders Equity
=8788/17530
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(8788 / 18264)*(18264 / 26826)*(26826 / 17530)
=Net Margin %*Asset Turnover*Equity Multiplier
=48.12 %*0.6808*1.5303
=ROA %*Equity Multiplier
=32.76 %*1.5303
=50.13 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %**(Q: Jun. 2022 )
=Net Income/Total Stockholders Equity
=8788/17530
=(Net Income /Pre-Tax Income) * (Pre-Tax Income/Operating Income) * (Operating Income/Revenue) * (Revenue/Total Assets) * (Total Assets/Total Stockholders Equity)
= (8788 / 9896) * (9896 / 9788) * (9788 / 18264) * (18264 / 26826) * (26826 / 17530)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.888 * 1.011 * 53.59 % * 0.6808 * 1.5303
=50.13 %

Note: The net income attributable to common stockholders data used here is four times the quarterly (Jun. 2022) net income attributable to common stockholders data. The Revenue data used here is four times the quarterly (Jun. 2022) revenue data. The same rule applies to Pre-Tax Income and Operating Income.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.


Be Aware

Net income attributable to common stockholders is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Moderna ROE % Related Terms

Thank you for viewing the detailed overview of Moderna's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Moderna Business Description

Moderna logo
Address
200 Technology Square, Cambridge, MA, USA, 02139
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Executives
Gomez Jorge M officer: See Remarks C/O DENTSPLY SIRONA INC 13320 BALLANTYNE CORPORATE PLACE CHARLOTTE NC 28277
Burton Paul officer: Chief Medical Officer 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Klinger Shannon Thyme officer: Chief Legal Officer 200 TECHNOLOGY SQUARE SUITE 300 CAMBRIDGE MA 02139
Le Goff Corinne officer: Chief Commercial Officer 200 TECHNOLOGY SQUARE SUITE 300 CAMBRIDGE MA 02139
Tallett Elizabeth E director 6705 ROCKLEDGE DR SUITE 900 BETHESDA MD 20817
Meline David W officer: Chief Financial Officer 3M COMPANY 3M OFFICE OF GENERAL COUNSEL ST PAUL MN 55144-1000
Horning Sandra director 333 LAKESIDE DRIVE FOSTER CITY CA 94404
Nader Francois director 550 HILLS DRIVE BEDMINSTER NJ 07921
Flagship Venturelabs Iv, Llc 10 percent owner 55 CAMBRIDGE PARKWAY, 8TH FLOOR CAMBRIDGE MA 02143
Sagan Paul director AKAMAI TECHNOLOGIES INC 8 CAMBRIDGE CENTER CAMBRIDGE MA 02142
Ruiz Israel director C/O FORTIVE CORPORATION 6920 SEAWAY BOULEVARD EVERETT WA 98203
Zaks Tal Zvi officer: Chief Medical Officer C/O ADAPTIMMUNE THERAPEUTICS PLC 60 JUBILEE AVE, MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Nabel Elizabeth G director BRIGHAM AND WOMEN'S HOSPITAL 75 FRANCIS ST BOSTON MA 02115
Hoge Stephen officer: President C/O MODERNA, INC. 200 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Henderson Lori M. officer: General Counsel and Secretary MOLDFLOW CORP 430 BOSTON POST ROAD WAYLAND MA 01778

Moderna Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)